miR-494 acts as an anti-oncogene in gastric carcinoma by targeting c-myc

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 7, 2014, Pages 1427-1434

  He, Weiling ^a   Li, Yuhuang ^a   Chen, Xinlin ^a   Lu, Liya ^b   Tang, Bin ^c   Wang, Zhixiong ^a   Pan, Yunbao ^d   Cai, Shirong ^a   He, Yulong ^a   Ke, Zunfu ^e  

^a First Affiliated Hospital   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

C myc; Gastric cancer; MicroRNAs; miR 494

Indexed keywords

ARGONAUTE 2 PROTEIN; BROXURIDINE; LUCIFERASE; MICRORNA; MICRORNA 494; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MIRN494 MICRORNA, HUMAN; MYC PROTEIN; MYC PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; BIOINFORMATICS; CANCER CELL; CANCER PROGNOSIS; CANCER TISSUE; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; FEMALE; FOLLOW UP; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; IN VIVO STUDY; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CARCINOMA; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; STOMACH NEOPLASMS; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE, SCID; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-MYC; STOMACH NEOPLASMS;

EID: 84903596361     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12558     Document Type: Article

References (35)

1. Uribesalgo I, Ballare C, Di Croce L. Polycomb regulates NF-kappaB signaling in cancer through miRNA. Cancer Cell 2012; 21: 5-7.
2. Helwak A, Kudla G, Dudnakova T, Tollervey D. Mapping the human miRNA interactome by CLASH reveals frequent noncanonical binding. Cell 2013; 153: 654-665.
3. Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM. Delivering the promise of miRNA cancer therapeutics. Drug Discov. Today 2013; 18: 282-289.
4. Wu D, Hu Y, Tong S, Williams BR, Smyth GK, Gantier MP. The use of miRNA microarrays for the analysis of cancer samples with global miRNA decrease. RNA 2013; 19: 876-888.
5. Zadran S, Remacle F, Levine RD. miRNA and mRNA cancer signatures determined by analysis of expression levels in large cohorts of patients. Proc. Natl Acad. Sci. U.S.A. 2013; 110: 19160-19165.
6. Saydam O, Senol O, Wurdinger T etal. miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Res. 2011; 71: 852-861.
7. Streicher KL, Zhu W, Lehmann KP etal. A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene 2012; 31: 1558-1570.
8. Jung HM, Patel RS, Phillips BL etal. Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions. Mol. Biol. Cell 2013; 24: 1638-1648, S1-7.
9. Shi ZM, Wang XF, Qian X etal. MiRNA-181b suppresses IGF-1R and functions as a tumor suppressor gene in gliomas. RNA 2013; 19: 552-560.
10. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol. Med. 2012; 4: 143-159.
11. Melo SA, Esteller M. Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett. 2011; 585: 2087-2099.
12. Hayashi T, Yoshikawa T, Bonam K etal. The superiority of the seventh edition of the TNM classification depends on the overall survival of the patient cohort: comparative analysis of the sixth and seventh TNM editions in patients with gastric cancer from Japan and the United Kingdom. Cancer 2013; 119: 1330-1337.
13. Pan HW, Li SC, Tsai KW. MicroRNA dysregulation in gastric cancer. Curr. Pharm. Des. 2013; 19: 1273-1284.
14. Li X, Luo F, Li Q etal. Identification of new aberrantly expressed miRNAs in intestinal-type gastric cancer and its clinical significance. Oncol. Rep. 2011; 26: 1431-1439.
15. Romano G, Acunzo M, Garofalo M etal. MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc. Natl Acad. Sci. U.S.A. 2012; 109: 16570-16575.
16. Lim L, Balakrishnan A, Huskey N etal. MiR-494 within an oncogenic MicroRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of MCC. Hepatology 2013; 59: 202-215.
17. Olaru AV, Ghiaur G, Yamanaka S etal. MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology 2011; 54: 2089-2098.
18. Liu S, Li Y, Zhang Z etal. Alpha(1)-Adrenergic receptors mediate combined signals initiated by mechanical stretch stress and norepinephrine leading to accelerated mouse vein graft atherosclerosis. J. Vasc. Surg. 2013; 57: 1645-1656.
19. Zhang Z, Zhang M, Li Y etal. Simvastatin inhibits the additive activation of ERK1/2 and proliferation of rat vascular smooth muscle cells induced by combined mechanical stress and oxLDL through LOX-1 pathway. Cell. Signal. 2013; 25: 332-340.
20. Rinn JL, Kertesz M, Wang JK etal. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007; 129: 1311-1323.
21. He WL, Li YH, Yang DJ etal. Combined evaluation of centromere protein H and Ki-67 as prognostic biomarker for patients with gastric carcinoma. Eur. J. Surg. Oncol. 2013; 39: 141-149.
22. Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett. 2011; 306: 171-179.
23. Kota J, Chivukula RR, O'Donnell KA etal. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137: 1005-1017.
24. Lal A, Navarro F, Maher CA etal. miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. Mol. Cell 2009; 35: 610-625.
25. Cenik ES, Zamore PD. Argonaute proteins. Curr. Biol. 2011; 21: R446-449.
26. Dang CV. MYC on the path to cancer. Cell 2012; 149: 22-35.
27. Dang CV. Therapeutic targeting of Myc-reprogrammed cancer cell metabolism. Cold Spring Harb. Symp. Quant. Biol. 2011; 76: 369-374.
28. de Souza CR, Leal MF, Calcagno DQ etal. MYC deregulation in gastric cancer and its clinicopathological implications. PLoS ONE 2013; 8: e64420.
29. Yamanaka S, Campbell NR, An F etal. Coordinated effects of microRNA-494 induce G(2)/M arrest in human cholangiocarcinoma. Cell Cycle 2012; 11: 2729-2738.
30. Meyerson M, Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol. Cell. Biol. 1994; 14: 2077-2086.
31. Stein U, Walther W, Arlt F etal. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat. Med. 2009; 15: 59-67.
32. Etienne-Manneville S, Hall A, Rho GT. Pases in cell biology. Nature 2002; 420: 629-635.
33. Kim WK, Park M, Kim YK etal. MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation. Clin. Cancer Res. 2011; 17: 7584-7594.
34. Kawate S, Fukusato T, Ohwada S, Watanuki A, Morishita Y. Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression. Oncology 1999; 57: 157-163.
35. Little CD, Nau MM, Carney DN, Gazdar AF, Minna JD. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 1983; 306: 194-196.